Aminoglycoside interference in the pyrogallol red-molybdate protein assay is increased by the addition of sodium dodecyl sulfate to the dye reagent.

References 1. Goldstein JA, de Morais SMF. Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics 1994;4:285–99. 2. Xie HG, Prasad HC, Kim RB, Stein CM. CYP2C9 allelic variants: ethnic distribution and functional significance. Adv Drug Deliv Rev 2002;54: 1257–70. 3. Linder MW. Genetic mechanisms for hypersensitivity and resistance to the anticoagulant warfarin. Clin Chim Acta 2001;308:9–15. 4. Sullivan-Klose TH, Ghanayem BI, Bell DA, Zhang ZY, Kaminsky LS, Shenfield GM, et al. The role of the CYP2C9-Leu allelic variant in the tolbutamide polymorphism. Pharmacogenetics 1996; 6:341–9. 5. Burian M, Grosch S, Tegeder I, Geisslinger G. Validation of a new fluorogenic real-time PCR assay for detection of CYP2C9 allelic variants and CYP2C9 allelic variant in a German population. Br J Clin Pharmacol 2002;54:518–21. 6. Borlak J, Thum T. Identification of major CYP2C9 and CYP2C19 polymorphisms by fluorescence resonance energy transfer analysis. Clin Chem 2002;48:1592–4.